-
Professor Ben Lv: Research Progress on Severe Coagulopathy | The 13th National Conference on Hematopoietic Stem Cell Transplantation Academic Conference of the Chinese Medical Association
Severe coagulopathy poses a serious threat to human life and health, with disseminated intravascular coagulation (DIC) being a common severe coagulopathy characterized by rapid development, dangerous progression, and high mortality. In recent years, Professor Ben Lv from the Second Xiangya Hospital of Central South University has conducted a series of original research studies on the…
-
Hematopoietic Stem Cell Transplantation is Approaching a “New” Breakthrough Moment | The 13th National Hematopoietic Stem Cell Transplantation Academic Conference of the Chinese Medical Association
In the bright spring of March, various flowers are blooming. The “13th National Hematopoietic Stem Cell Transplantation Academic Conference of the Chinese Medical Association,” hosted by the Chinese Medical Association and organized by the National Clinical Research Center for Hematologic Diseases – Peking University Institute of Hematology, was grandly held from March 1st to 2nd…
-
Professor Depei Wu: Inheriting, Innovating, and Developing to Promote High-Quality Development in Hematology | The 13th National Conference on Hematopoietic Stem Cell Transplantation of the Chinese Medical Association
With the arrival of spring, the 13th National Conference on Hematopoietic Stem Cell Transplantation of the Chinese Medical Association, hosted by the National Clinical Research Center for Hematologic Diseases and organized by Peking University Institute of Hematology, was grandly held in Beijing from March 1st to 2nd. This conference centered around the basic and clinical…
-
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
In 2022, a groundbreaking study led by Professor Xiaojun Huang from Peking University Institute of Hematology, was published in the prestigious Journal of Hematology & Oncology. The study is titled “Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.” This…
-
Mixed Chimerism and Its Impact on Long-term Failure-free Survival in Aplastic Anemia Patients Undergoing HLA-matched Donor Transplantation
In January 2024, a groundbreaking study spearheaded by Professor Xiaojun Huang from Peking University Institute of Hematology, was featured in the distinguished international journal — Bone Marrow Transplantation . The research, titled “Mixed Chimerism and Its Influence on Long-term Failure-free Survival in Aplastic Anemia Patients Undergoing HLA-Matched Donor Transplantation” delivers new insights into the prognosis…
-
Comparison of Haploidentical Hematopoietic Stem Cell Transplantation with Chemotherapy in Older Adults with Acute Myeloid Leukemia
In 2023, a groundbreaking study spearheaded by Professor XiaoJun Huang from Peking University Institute of Hematology, made its debut in a prestigious international academic journal——Bone Marrow Transplantation. This pivotal research, entitled “Comparison of Haploidentical Hematopoietic Stem Cell Transplantation with Chemotherapy in Older Adults with Acute Myeloid Leukemia” offers a novel perspective on treatment efficacy for…
-
Impacts of Early Therapy Response, Interval to Therapy Interruption, and Cumulative Therapy Interruption Duration on Outcome of Ibrutinib Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia
In July 2023, a groundbreaking study led by Professor Xiaojun Huang from Peking University Institute of Hematology was published in a prestigious academic journal ——Annals of Hematolog. The study, titled “Impacts of Early Therapy Response, Interval to Therapy Interruption, and Cumulative Therapy Interruption Duration on Outcome of Ibrutinib Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia” marks…
-
External validation of the predictive scoring systems formolecular responses in chronic myeloid leukaemia receivinginitial imatinib-therapy
In July 2023, a significant study led by Professor Xiaojun Huang from Peking University Institute of Hematology was published in Leukemia, focusing on chronic myeloid leukemia (CML) treatment with imatinib. This research introduced and validated a predictive scoring system to forecast molecular responses in CML patients. The study, involving an external validation on a cohort…
Connecting Medical Expertise through Media